Biology & biomedicine Success stories
A spin-off company will develop a monoclonal antibody to treat autoimmune diseases such as psoriasis
- Details
- Category: Success stories
-
29 Dec 2021
The antibody acts on the immune system to increase anti-inflammatory activity and attenuate inflammation. It will be developed by the Inhibitec Anticuerpos company, created by the scientists who created the technology at the CSIC and the University of Cantabria.
Bio-nanocellulose meshes improve hernia repair surgery
- Details
- Category: Success stories
-
20 Apr 2021
Researchers from the Institute of Materials Science of Barcelona (ICMAB-CSIC) and B. Braun Surgical, a leading manufacturer of medical devices for wound closure, have collaborated to develop a bio-based surgical mesh with this biomaterial. First results from an in vivo animal study yield promising outcomes.
Antibodies test for Covid-19 with near 100% accuracy
- Details
- Category: Success stories
-
29 Dec 2020
A new serological test for Covid-19 with an accuracy close to 100% has been developed by researchers from the CSIC, in collaboration with the hospitals of La Princesa and La Paz. The Spanish biotechnology company Immunostep produces and commercializes the test.
A more effective nanomedicine has been developed for the treatment of Fabry rare disease
- Details
- Category: Success stories
-
26 Feb 2021
This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work. The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future. The new drug improves on current treatments and helps reduce costs and improve patients' quality of life.
Gut bacteria to treat depression and anxiety
- Details
- Category: Success stories
-
30 Apr 2020
CSIC researchers have patented a gut bacteria called Christensenella minuta that has therapeutic applications to treat mood disorders, such as depression and anxiety. This technology has been developed by a team at the Institute of Agrochemistry and Food Technology (IATA-CSIC), and has has already been licensed to LNC Therapeutics, a French biotechnology company specialized in research and development of drugs in the area of the intestinal microbiome.
